The RELIVE consortium for relapsed or refractory pediatric hepatoblastoma and hepatocellular carcinoma: a scoping review of the problem and a proposed solutionResearch in context

The RELIVE consortium for relapsed or refractory pediatric hepatoblastoma and hepatocellular carcinoma: a scoping review of the problem and a proposed solutionResearch in context

Summary: Liver tumors account for approximately 2% of all pediatric malignancies. Children with advanced stages of hepatoblastoma (HB) are cured only 50–70% of the time while children with advanced hepatocellular carcinoma (HCC) have a <20% 5-year overall survival. This scoping review was perform...

Full description

Bibliographic Details
Main Authors: Allison F. O’Neill, Angela Trobaugh-Lotrario, James I. Geller, Eiso Hiyama, Kenichiro Watanabe, Isabelle Aerts, Brice Fresneau, Fabienne Toutain, Michael J. Sullivan, Howard M. Katzenstein, Bruce Morland, Sophie Branchereau, József Zsiros, Rudolf Maibach, Marc Ansari
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:EClinicalMedicine
Subjects:
Review
Pediatric
Relapse
Hepatoblastoma
Carcinoma
Registry
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537024000257

Internet

http://www.sciencedirect.com/science/article/pii/S2589537024000257

Similar Items